Comparison of anti-invasive activity of parthenolide and 3-isopropyl-2-methyl-4-methyleneisoxazolidin-5-One (MZ-6) - A new compound with α-methylene-γ-lactone motif - On two breast cancer cell lines

Chemical Biology and Drug Design

Volumn 79, Issue 1, 2012, Pages 112-120

  Wyrebska, Anna ^a   Gach, Katarzyna ^a   Szemraj, Janusz ^a   Szewczyk, Karolina ^a   Hrabec, Elzbieta ^a   Koszuk, Jacek ^b   Janecki, Tomasz ^b   Janecka, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Anticancer activity; Gene expression; Metastasis; Sesquiterpene lactones; Wound healing assay

Indexed keywords

3 ISOPROPYL 2 METHYL 4 METHYLENEISOXAZOLIDIN 5 ONE; ANTINEOPLASTIC AGENT; GELATINASE B; MESSENGER RNA; NITROGEN; PARTHENOLIDE; UNCLASSIFIED DRUG; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CYTOTOXICITY; DOWN REGULATION; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; FEMALE; HUMANS; ISOXAZOLES; LACTONES; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; SESQUITERPENES; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

TANACETUM PARTHENIUM;

EID: 84155188969     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01257.x     Document Type: Article

References (34)

1. Hoffmann H.M.R., Rabe J. (1985) Synthesis and biological activity of alfa-methylene-gamma-butyrolactones. Angew Chem Int Ed Engl;24:94-110.
2. Zhang S., Won Y.K., Ong C.N., Shen H.M. (2005) Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents;5:239-249.
3. Konishi T., Shimada Y., Nagao T., Okabe H., Konoshima T. (2002) Antiproliferative sesquiterpene lactones from the roots of Inula helenium. Biol Pharm Bull;25:1370-1372.
4. Won Y.K., Ong C.N., Shi X., Shen H.M. (2004) Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis;25:1449-1458.
5. Heilmann J., Wasescha M.R., Schmidt T.J. (2001) The influence of glutathione and cysteine levels on the cytotoxicity of helenanolide type sesquiterpene lactones against KB cells. Bioorg Med Chem;9:2189-2194.
6. Knight D.W. (1995) Feverfew: chemistry and biological activity. Nat Prod Rep;12:271-276.
7. Zhang S., Ong C.N., Shen H.M. (2004) Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett;208:143-153.
8. Nakagawa Y., Iinuma M., Matsuura N., Yi K., Naoi M., Nakayama T., Nozawa Y., Akao Y. (2005) A potent apoptosis-inducing activity of a sesquiterpene lactone, arucanolide, in HL60 cells: a crucial role of apoptosis-inducing factor. J Pharmacol Sci;97:242-252.
9. Rivero A., Quintana J., Eiroa J.L., Lopez M., Triana J., Bermejo J., Estévez F. (2003) Potent induction of apoptosis by germacranolide sesquiterpene lactones on human myeloid leukemia cells. Eur J Pharmacol;482:77-84.
10. Dirsch V.M., Stuppner H., Vollmar A.M. (2001) Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-x(L) or Bcl-2. Cancer Res;61:5817-5823.
11. Wen J., You K.R., Lee S.Y., Song C.H., Kim D.G. (2002) Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem;277:38954-38964.
12. Liu J.W., Cai M.X., Xin Y., Wu Q.S., Ma J., Yang P., Xie H.Y., Huang D.S. (2010) Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res;29:108.
13. Mendonca M.S., Chin-Sinex H., Gomez-Millan J., Datzman N., Hardacre M., Comerford K., Nakshatri H., Nye M., Benjamin L., Mehta S., Patino F., Sweeney C. (2007) Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair. Radiat Res;168:689-697.
14. Hehner S.P., Hofmann T.G., Droge W., Schmitz M.L. (1999) The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol;163:5617-5623.
15. Saadane A., Masters S., DiDonato J., Li J., Berger M. (2007) Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol;36:728-736.
16. Pajak B., Gajkowska B., Orzechowski A. (2008) Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol;46:129-135.
17. Janecki T., Wasek T., Rozalski M., Krajewska U., Studzian K., Janecka A. (2006) 4-Methylideneisoxazolidin-5-ones - a new class of alpha-methylidene-gamma-lactones with high cytostatic activity. Bioorg Med Chem Lett;16:1430-1433.
18. Rozalski M., Krajewska U., Panczyk M., Mirowski M., Rozalska B., Wasek T., Janecki T. (2007) Synthesis and biological evaluation of 4-methylideneisoxazolidin-5-ones - a new class of highly cytotoxic alpha-methylidene-gamma-lactones. Eur J Med Chem;42:248-255.
19. Krawczyk H., Albrecht Ł. (2005) Knoevenagel reaction of diethylphosphonoacetic acid: a facile route to diethyl (E)-2-arylvinylphosphonates. Synthesis;2005:2887-2896.
20. Berridge M.V., Tan A.S. (1993) Characterization of the cellular reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electrontransport in MTT reduction. Arch Biochem Biophys;303:474-482.
21. Liu Y., Peterson D.A., Kimura H., Schubert D. (1997) Mechanism of cellular 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem;69:581-593.
22. Rodriguez L.G., Wu X., Guan J.L. (2005) Wound-healing assay. Methods Mol Biol;294:23-29.
23. Yin Y., Chen X., Shu Y. (2009) Gene expression of the invasive phenotype of TNF-a-treated MCF-7 cells. Biomed Pharmacother;63:421-428.
24. Hrabec E., Strek M., Nowak D., Greger J., Suwalski M., Hrabec Z. (2002) Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol;128:197-204.
25. Kitson R.R.A., Millemaggi A., Taylor R.J.K. (2009) The renaissance of α-methylene-γ-butyrolactones: new synthetic approaches. Angew Chem Int Ed;48:9426-9451.
26. Albrecht A., Albrecht Ł., Janecki T. (2011) Recent advances in the synthesis of α-alkylidene-δ-lactones, α-alkylidene-γ-lactams and α-alkylidene-δ-lactams. Eur J Org Chem;2011:2747-2766.
27. Steeg P.S., Theodorescu D. (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol;5:206-219.
28. Geiger T.R., Peeper D.S. (2009) Metastasis mechanisms. Biochim Biophys Acta;1796:293-308.
29. Engbring J.A., Kleinman H.K. (2003) The basement membrane matrix in malignancy. J Pathol;200:465-470.
30. Widel M.S., Widel M. (2006) Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. Postepy Hig Med Dosw (Online);60:453-470.
31. Shariftabrizi A., Nifli A.P., Ansari M., Saadat F., Ebrahimkhani M.R., Alizadeh N., Nasseh A., Alexaki V.I., Dehpour A.R., Castanas E., Khorramizadeh M.R. (2006) Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Eur J Pharmacol;530:33-39.
32. Das S., Banerji A., Frei E., Chatterjee A. (2008) Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci;82:467-476.
33. Duffy M.J. (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des;10:39-49.
34. Duffy M.J., Duggan C. (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer. Clin Biochem;37:541-548.